Myopia: a growing global problem with sight-threatening complications
Related content
Globally, myopia is the leading cause of distance refractive error, affecting 1.45 billion or 27% of the world’s population in 2010 (myopia being defined as more than or equal to 0.50 D of myopia).1 The number of people with myopia is expected to continue to rise both in absolute numbers and as a percentage of the population.2 In certain age groups in several Asian countries, the prevalence of myopia is over 80%. Among late teenagers and young adults in Korea, Taiwan and China the prevalence is now between 84% and 97%.3-5
In addition to the increase in prevalence, there is evidence of a rise in the severity of myopia.3 A study by Vitale et al.6 in the United States found that the prevalence of moderate myopia, defined as between –2.00 D and –7.9 D, nearly doubled (from 11.4% in 1971–1972 to 22.4% in 1999–2004), and that the prevalence of high myopia, which was defined as more than 8.00 D of myopia for this study, had increased eightfold during the same period (from 0.2% to 1.6%). The global prevalence of high myopia (commonly defined as greater than or equal to 5.00 D of myopia) was 2.9% (224 million people) in 2010.7
Risks
High myopia is associated with an increased risk of developing sightthreatening conditions such as myopic macular degeneration (defined as atrophic changes or choroidal neovscularisation in the macular region in high myopia), retinoschisis, posterior staphyloma, glaucoma retinal detachment, and cataract.8,9 A literature review found that the prevalence of vision impairment due to pathologic myopia (high myopia with one or more typical fundus lesions) is between 0.1% and 0.5% in European studies and between 0.2% and 1.4% in Asian studies.9 In a Japanese study, 12.2% of vision impairment was caused by pathologic myopia.10 Myopic macular degeneration has been reported to be the major cause of monocular blindness in Tajimi, Japan,11 and the leading cause of new cases of blindness in Shanghai, China.12 Without interventions to slow the progress of myopia, the prevalence of pathologic myopia can be expected to increase.
Causes and cures
Myopia development and progression is considered to be multifactorial, with genetic and environmental factors contributing, although the contribution of genetics is considered small. Genes have been identified for myopia13,14 but genes are thought to determine one’s susceptibility to environmental factors.15 Several environmental factors have been identified,15-18 including too much time spent on near work;18 insufficient time spent outdoors;19 low levels of vitamin D;20 inadequate light exposure;21 and poor diet.22 There is evidence emerging that increased time spent outdoors can reduce the risk of developing myopia and – in those with myopia – it can reduce the rate of progression.23,24 Reduced rates of progression in summer compared to winter25 also supports the hypothesis of the light theory. It has also been shown in experimental animal models that a defocused retinal image can lead to axial elongation of the eye, and hence myopia. While it seems unlikely that there will be a treatment that can completely prevent myopia development and progression, there are some promising treatments on the horizon. These include providing a focussed image at all retinal locations to remove the stimulus to axial eye elongation. Executive bifocal spectacles,26 peripheral plus contact lenses,27 extended depth of focus contact lenses28 and orthokeratology29 are some of the optical intervention methods that show some efficacy in reducing the rate of progression of myopia (some by up to 51%). Pharmacological agents such as 0.01% atropine are being prescribed in Asia, and show a reduction of up to 50% in the rate of progression of myopia, although there is no reduction in the rate of axial elongation.30 Oral tablets containing 7-methylxanthine (7-MX) have been approved for use in children in Denmark for myopia control and shows some efficacy, but long-term studies are needed.31 While these approaches have been tried in isolation, they may have a greater impact if different approaches are combined.
Discussion
Uncorrected distance refractive error is already a major global health problem. It is the main cause of vision impairment and the second highest cause of blindness.32 It has also been estimated to cost about US $202 billion33 in global lost productivity. However, whereas uncorrected refractive error is the second major cause of blindness, this does not include blindness from pathologic myopia; nor does the estimate of the financial burden of uncorrected refractive error take into account blindness due to pathologic myopia.
Myopia can no longer be considered a benign refractive error, easily corrected with a pair of spectacles or contact lenses. It has an insidious side which, even if adequately corrected, can sometimes progress and may lead to sight-threatening complications. Current forms of correction for myopia (spectacles, contact lenses and refractive surgery), do not cure the underlying myopia but provide an optical solution for clear vision and thus do not offer any protection from the consequences of high myopia.
Given that myopia is already one of the major causes of vision impairment and blindness, and is projected to affect almost half of the world’s population within 40 years,2 urgent action is demanded from governments, non-government organisations and researchers. Policy makers must recognise the risk of increasing myopia and ensure that appropriate detection and treatment is available. Myopia control is possible but clinicians must adopt myopia control strategies as soon as a child becomes myopic. Parents should also be encouraged to monitor the time their children spend on near devices and encourage time spent outdoors.
Further reading
Prevalence and Pathologies of High Myopia. Mivision, 28 July 2015
References
1. Vision CRC
2. Holden, BA et al. in Association for Research in Vision and Ophthalmology.
3. Lin LL, Shih Y F, Hsiao CK and Chen CJ. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore. 2004;33: 27–33
4. Wang TJ, Chiang TH, Wang TH, Lin LLK and Shih YF. Changes of the ocular refraction among freshmen in National Taiwan University between 1988 and 2005. Eye 2008;23: 1168–1169.
5. Jung SK, Lee JH, Kakizaki H and Jee D. Prevalence of myopia and its association with body stature and educational level in 19-year-old male conscripts in Seoul, South Korea. Invest Ophthalmol Vis Sci 2012;53: 5579–5583.
6. Vitale S, Sperduto RD and Ferris III FL. Increased prevalence of myopia in the United States between 1971–1972 and 1999–2004. Arch Ophthalmol 2009;127: 1632–1639.
7. Holden BA in American Academy of Optometry (Denver, USA, 2014).
8. Spaide RF, Ohno-Matsui K and Yannuzzi LA. Pathologic Myopia. New York: Springer Science and Business Media, 2014.
9. Wong TY, Ferreira A, Hughes R, Carter G and Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157, 9–25.
10. Yamada M et al. prevalence of visual impairment in the adult japanese population by cause and severity and future projections. Ophthal Epidemiol 2010;17: 50–57.
11. Iwase A et al. prevalence and causes of low vision and blindness in a japanese adult population: the Tajimi Study. Ophthalmology 2006;113: 1354–1362.
12. Wu L, Sun X, Zhou X and Weng C. Causes and 3-year-incidence of blindness in Jing-An District, Shanghai, China 2001-2009. BMC Ophthalmol 2011;11: 10.
13. Farbrother JE et al. Linkage analysis of the genetic loci for high myopia on 18p, 12q, and 17q in 51 UK Families. Investigative ophthalmology & visual science 2014;45: 2879–2885.
14. Kiefer, A. K. et al. Genome-wide analysis points to roles for extracellular matrix remodeling, the visual cycle, and neuronal development in myopia. PLoS Genet 9, 2013; Epub Feb 28.
15. Lim LT et al. Impact of parental history of myopia on the development of myopia in mainland China school-aged children. Ophthalmology and Eye Diseases 2014;6: 31–35.
16. Fledelius HC, Goldschmidt E, Haargaard B and Jensen H. Human parallels to experimental myopia? A literature review on visual deprivation. Acta Ophthalmol 2014; Epub Apr 27.
17. Flitcroft DI. Emmetropisation and the aetiology of refractive errors. Eye 2014;28: 169–179. Epub Jan 10.
18. Morgan IG, Ohno-Matsui K and Saw SM. Myopia. Lancet 2012;379: 1739–1748
19. French AN, Ashby, RS, Morgan IG and Rose KA. Time outdoors and the prevention of myopia. Exp Eye Res 2013;114: 58–68. Epub May 22.
20. Yazar, S. et al. Myopia is associated with lower vitamin D status in young adults. Invest Ophthalmol Vis Sci 2014; doi:10.1167/iovs.14-14589.
21. Read SA, Collins MJ and Vincent SJ. Light exposure and physical activity in myopic and emmetropic children. Optom Vis Sci 2014;91: 330–341.
22. Lim LS et al. Dietary factors, myopia, and axial dimensions in children. Ophthalmol 2010;117: 993–997.
23. Wu PC, Tsai CL, Wu HL, Yang YH and Kuo HK. Outdoor activity during class recess reduces myopia onset and progression in school children. Ophthalmol 2013;120: 1080–1085.
24. Morgan IG. et al. Increased outdoor time reduces incident myopia – the Guangzhou outdoor activity longitudinal study. Invest Ophtalmol Vis Sci 2014;55: 1272.
25. Donovan L et al. Myopia progression in Chinese children is slower in summer than in winter. Optom Vision Sci 2012:89, 1196–1202.
26. Cheng D, Woo GC, Drobe B and Schmid KL. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: three-year results of a randomized clinical trial. JAMA Ophthalmol 2014;132(3): 285–64.
27. Sankaridurg P et al. Decrease in rate of myopia progression with a contact lens designed to reduce relative peripheral hyperopia: one-year results. Invest Ophtalmol Vis Sci 2011;52(13): 9362–7.
28. Bakaraju, R. C. et al. in Association for Research in Vision and Ophthalmology (Denver, USA, 2015).
29. Si JK et al. Orthokeratology for myopia control: a meta-analysis. Optom Vis Sci 2015;92(3): 252–7.
30. Chia A et al, Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmol 2012;119(2): 347–54.
31. Nie HH et al. Effects of 7-methylxanthine on form-deprivation myopia in pigmented rabbits. Int J Ophthalmol 2012;5(2): 133–7.
32. Bourne RR. et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. The Lancet Glob Health 2013;1(6):e339–49.
33. Fricke, T. et al. Global cost of correcting vision impairment from uncorrected refractive error. Bull World Health Organ. 2012;90(10): 728–38.
Sponsored by the Brien Holden Vision Institute www.brienholdenvision.org